ErbB receptor partial agonists have already been translated to clinical practice, as the FDA-approved anti-ErbB2 monoclonal antibody transtuzumab stimulates ErbB2 tyrosine phosphorylation and downregulation, resulting in reduced ErbB2-dependent tumor cell proliferation [27]. The gene discussed is ERBB2; the disease is neoplasm.